CL2023003259A1 - Composiciones y métodos para el tratamiento de la depresión. - Google Patents

Composiciones y métodos para el tratamiento de la depresión.

Info

Publication number
CL2023003259A1
CL2023003259A1 CL2023003259A CL2023003259A CL2023003259A1 CL 2023003259 A1 CL2023003259 A1 CL 2023003259A1 CL 2023003259 A CL2023003259 A CL 2023003259A CL 2023003259 A CL2023003259 A CL 2023003259A CL 2023003259 A1 CL2023003259 A1 CL 2023003259A1
Authority
CL
Chile
Prior art keywords
patient
treatment
methods
aticaprant
reuptake inhibitor
Prior art date
Application number
CL2023003259A
Other languages
English (en)
Spanish (es)
Inventor
Schmidt Mark
Popova Vanina
Savitz Adam
Melkote Rama
C Drevets Wayne
Gopal Srihari
Pemberton Darrel
Lagishetty Chakradhar
Lva Kezic
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/307,858 external-priority patent/US11266627B1/en
Priority claimed from US17/670,123 external-priority patent/US12161622B2/en
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of CL2023003259A1 publication Critical patent/CL2023003259A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatment And Processing Of Natural Fur Or Leather (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CL2023003259A 2021-05-04 2023-11-02 Composiciones y métodos para el tratamiento de la depresión. CL2023003259A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/307,858 US11266627B1 (en) 2021-05-04 2021-05-04 Compositions and methods for the treatment of depression
US17/670,123 US12161622B2 (en) 2021-05-04 2022-02-11 Compositions and methods for the treatment of depression
US202263313792P 2022-02-25 2022-02-25

Publications (1)

Publication Number Publication Date
CL2023003259A1 true CL2023003259A1 (es) 2024-05-31

Family

ID=81654924

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023003259A CL2023003259A1 (es) 2021-05-04 2023-11-02 Composiciones y métodos para el tratamiento de la depresión.

Country Status (16)

Country Link
EP (1) EP4333835A1 (https=)
JP (1) JP2024516297A (https=)
KR (1) KR20240004857A (https=)
AU (1) AU2022268720A1 (https=)
BR (1) BR112023023030A2 (https=)
CA (1) CA3219079A1 (https=)
CL (1) CL2023003259A1 (https=)
CO (1) CO2023015571A2 (https=)
IL (1) IL308221A (https=)
JO (1) JOP20230276A1 (https=)
MX (1) MX2023013040A (https=)
PE (1) PE20241784A1 (https=)
PH (1) PH12023552963A1 (https=)
TW (1) TW202313003A (https=)
UY (1) UY39754A (https=)
WO (1) WO2022234457A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
WO2023170547A1 (en) * 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant
EP4489730B1 (en) 2022-03-07 2026-01-21 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
WO2024216046A1 (en) * 2023-04-13 2024-10-17 Neumora Therapeutics, Inc. Methods of treating anhedonia
WO2024216061A1 (en) * 2023-04-13 2024-10-17 Neumora Therapeutics, Inc. Methods of treating depression and anhedonia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009094260A1 (en) 2008-01-22 2009-07-30 Eli Lilly And Company Kappa selective opioid receptor antagonist

Also Published As

Publication number Publication date
CA3219079A1 (en) 2022-11-10
JOP20230276A1 (ar) 2023-11-02
BR112023023030A2 (pt) 2024-02-15
TW202313003A (zh) 2023-04-01
WO2022234457A1 (en) 2022-11-10
EP4333835A1 (en) 2024-03-13
CO2023015571A2 (es) 2023-11-30
AU2022268720A1 (en) 2023-12-21
UY39754A (es) 2022-11-30
PH12023552963A1 (en) 2024-03-11
IL308221A (en) 2024-01-01
JP2024516297A (ja) 2024-04-12
MX2023013040A (es) 2024-01-05
KR20240004857A (ko) 2024-01-11
PE20241784A1 (es) 2024-09-06

Similar Documents

Publication Publication Date Title
CL2023003259A1 (es) Composiciones y métodos para el tratamiento de la depresión.
MX2024010140A (es) Nuevos metodos.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
CO2023002206A2 (es) Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas trem2
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
EA202091597A1 (ru) Способы и композиции для лечения апноэ сна
KR980000447A (ko) 미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물
MY206999A (en) Treatment of hidradenitis suppurativa using jak inhibitors
BR112021020247A2 (pt) Composições e métodos para melhorar a saúde da pele e para o tratamento e prevenção de doenças, distúrbios e afecções associadas a micróbios patogênicos
AR077573A2 (es) Uso de un inhibidor de tnf y composicion farmaceutica que lo comprende
MX2015012760A (es) Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma.
DE602006021444D1 (de) Therapie zur behandlung der überaktiven blase
AR047719A1 (es) Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion que comprenden un ligando alfa-2-delta y un ssri y/o un snri
MX2021006985A (es) Metodos para el tratamiento de la depresión.
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
AR119033A1 (es) Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa
CO6280474A2 (es) Composicion farmaceutica para el tratamiento de la eyaculacion precoz
MX2023009600A (es) Análogos de la oxa-ibogaína para el tratamiento de trastornos por consumo de sustancias.
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
AR045423A1 (es) Combinaciones de analiticos y antidepresivos
IL315409A (en) Polymorph forms of aticaprant for use in treating major depressive disorder
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
ECSP23027106A (es) Formulación combinada oral que incluye gemigliptina y dapagliflozina y método de preparación para la misma
MX2024008618A (es) Composiciones y métodos para el tratamiento de la depresión.
AR047716A1 (es) Combinaciones de analepticos y antidepresivos